# Retatrutide Half-Life and Pharmacokinetics — Medicine Retatrutide > Retatrutide half life: approximately 6 days in human plasma. Phase 1b PK data, albumin-binding mechanism, and once-weekly dosing rationale. Cited from published trials. Half-life data from Phase 1b first-in-human studies, the albumin-binding mechanism, and the pharmacokinetic rationale for once-weekly dosing. ## What the half-life means in plain terms Half-life is the time it takes for the concentration of a drug in the blood to fall by half. For retatrutide, that is approximately 6 days. This matters because it tells you how often the drug needs to be injected to keep enough of it in the body — in this case, once a week. It also tells you that after stopping, the drug stays in the body for about 30–36 days before it reaches near-undetectable levels (roughly 5–6 half-lives). The 6-day half-life was measured in the first-in-human Phase 1b study in adults with type 2 diabetes. It is what drives the once-weekly injection schedule used in all retatrutide trials to date. The extended half-life is not a natural property of the retatrutide peptide itself — it is engineered by a chemical modification that makes the drug cling to albumin, the main carrier protein in blood, which acts as a slow-release reservoir. Without that modification, the peptide would clear in hours. This engineering is also what keeps the [retatrutide half life](/half-life) study results consistent across dose groups in Phase 1b. ## Phase 1b pharmacokinetics data The first-in-human Phase 1b pharmacokinetic study (Urva et al., *Lancet*, 2022) enrolled 72 adults with type 2 diabetes and HbA1c 7.0–10.5%. Dose groups received once-weekly subcutaneous retatrutide at 0.5 mg, 1.5 mg, 3 mg, 3/6 mg, and 3/6/9/12 mg (multi-ascending doses within a group) over 12 weeks [4]. Key pharmacokinetic findings: - **Half-life: ~6 days.** Consistent across dose groups; supports once-weekly dosing with stable trough-to-peak plasma concentration ratios. - **Absorption route: subcutaneous.** All doses were injected into subcutaneous adipose tissue (fat layer under skin). No IV or oral formulation was studied. - **Weight loss (pharmacodynamic endpoint): −8.96 kg placebo-adjusted** at the highest dose group over 12 weeks (90% CI: −11.16 to −6.75 kg) [4]. - **Daily glucose reduction: −2.8 mmol/L** at 3 mg. - **Treatment-emergent adverse events: 63%**, predominantly GI. Acceptable safety profile. The Phase 1b study was preceded by NCT04143802, Eli Lilly's Phase 1 single/multiple ascending-dose study in healthy participants establishing initial safety and PK [7]. ## Structural basis of extended half-life Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone. Its molecular formula is C221H342N46O68 (free acid), molecular weight approximately 4731.33 Da. The extended plasma half-life is engineered by a C20 fatty-diacid acyl chain attached to the peptide [3]. Fatty-acid acylation is the same engineering strategy used to extend the half-lives of other GLP-1-class compounds. The C20 chain binds non-covalently to albumin (the most abundant protein in plasma), which: 1. Acts as a slow-release depot, releasing free retatrutide gradually 2. Dramatically reduces renal clearance (kidneys cannot filter the large albumin-bound complex) 3. Protects the peptide from peptidase degradation The binding affinity at GIPR is approximately 8.9× that of native GIP; at GCGR and GLP-1R it is 0.3× and 0.4× native hormones respectively — potency that was specifically tuned during the drug's design to balance receptor arms [3]. The cryo-EM structural study (Li et al., *Cell Discovery*, 2024) resolved how retatrutide engages all three receptor complexes. At GLP-1R and GCGR, the peptide's N-terminal ECL1 (extracellular loop 1) adopts a rigid alpha-helix; at GIPR it adopts a flexible loop. The structural flexibility at GIPR is believed to contribute to its higher relative GIPR potency [3]. ## Pharmacokinetics and once-weekly dosing rationale The ~6-day half-life means plasma concentration peaks within approximately 24 hours post-injection, then declines to a trough level over the next 6 days. By injection day 7, concentration is approximately 50% of the peak. The trough concentration is still well within the receptor-active range — this is why steady-state drug exposure is maintained with once-weekly injections without wide peak-to-trough swings. By comparison, the first generation of GLP-1 agonists had half-lives of hours (liraglutide: ~13 hours, requiring once-daily dosing). Longer-acting compounds in the class — engineered with similar fatty-acid albumin-binding chemistry — achieve weekly dosing. The 2025 pipeline review (Madsbad et al., *Expert Opinion on Investigational Drugs*) discussed PK/PD profiles of GLP-1 mono-, dual-, and triple-agonists, identifying the pharmacokinetic class principle: extended half-life via fatty-acid acylation enables once-weekly dosing and smooths out peak-related GI side effects compared with shorter-acting agents [12]. For context on what the drug does at the receptors the PK delivers it to, see [how does retatrutide work](/how-it-works). ## Gray-market material and PK uncertainty The approximately 6-day half-life was measured in pharmaceutical-grade investigational product of verified identity, potency, and sterility, administered under clinical trial conditions. These figures do not apply to gray-market research-labeled material, which has no verified identity or concentration. If the material does not contain authentic retatrutide at the labeled concentration — which independent analyses of similar gray-market peptides have found to be a real risk — the pharmacokinetics would be entirely different. There is no validated storage, reconstitution, or handling specification for non-trial retatrutide. These are not abstract warnings — they are the direct consequences of the compound's investigational status. --- An apothecary's specimen record of the retatrutide pharmacokinetics literature — trial findings documented to source, no dispensary behind the cabinet, no prescription filled here.